| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.049 | 0.8 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |